Early studies in nerve cells and a rat model of Parkinson’s disease support the potential of fosgonimeton, also known as ATH-1017, to be neuroprotective and possibly disease modifying, Athira Pharma, the therapy’s developer, reported. Data from preclinical work showed that the therapy increased cell survival in the…
News
InMed Pharmaceuticals will launch a new program – the INM-900 series – that will investigate the therapeutic potential of its cannabinoid analogs in neurodegenerative diseases, including Parkinson’s, the company announced in a press release. Cannabinoids, also called phytocannabinoids, are the active chemicals that give the cannabis plant…
DiagnaMed Holdings will develop a virtual reality and artificial intelligence tool (VR/AI Neuro) for the diagnosis of neurodegenerative diseases, such as Parkinson’s disease. The company acquired an exclusive worldwide license of intellectual property from the KU Center for Technology Commercialization, at the University of Kansas, for the…
Levels of neurofilament light chain (NfL) protein in the bloodstream of people with Parkinson’s disease can independently predict cognitive decline, a recent study suggests. Although p-tau181 concentration, a biomarker in Alzheimer’s disease, which is the most common cause of dementia, was higher in Parkinson’s patients, links to cognitive performance…
Difficulty in swallowing medications, either tablets or capsules, was common among people with Parkinson’s disease, a study reports. This impairment in swallowing, called dysphagia, also predicted worse motor complications, and data suggest capsules tended to be easier to swallow than tablets. Evidence of swallowing difficulties for food is a…
Toxic clumps of the alpha-synuclein protein, the underlying cause of neurodegeneration in Parkinson’s disease, may originate in the digestive tract before migrating to the brain, a study in mice reported, supporting previous work into a gut-brain axis in disease development. Changes to microbes in the digestive tract, known…
Nitrase Therapeutics showed suppressing the activity of an enzyme called synuclein nitrase reduces toxic clumps of the alpha-synuclein protein and normalizes the electrical activity of dopamine-producing, or dopaminergic, neurons derived from Parkinson’s patients. The accumulation of toxic alpha-synuclein clumps is the underlying cause of the progressive death of…
MeiraGTx’s new Phase 1/2 clinical trial of AAV-GAD, its investigational gene therapy for Parkinson’s disease, has started dosing patients, the company announced in a press release. “We are now dosing patients with adeno-associated virus (AAV) encoding glutamic acid decarboxylase (AAV-GAD), an investigational gene therapy product…
Being exposed to insecticides impacts gastrointestinal function and might increase the risk of developing Parkinson’s disease, a new study in mice shows. The research also shows exposure to a specific insecticide disrupts dopaminergic brain circuitries, and leads to motor deficits associated with Parkinson’s. When it comes to neurological disorders,…
The U.S. Food and Drug Administration (FDA) will review Amneal Pharmaceuticals’ application for IPX203, its extended-release carbidopa/levodopa (CD/LD) tablet for Parkinson’s disease. Results from the Phase 3 RISE-PD clinical trial (NCT03670953) showed IPX203 can control Parkinson’s symptoms safely and effectively for longer periods with less frequent dosing,…
Recent Posts
- Choosing when to share a Parkinson’s diagnosis isn’t one-size-fits-all
- Parkinson’s Awareness Month to focus on education, finding real answers
- Our solution for staying on top of my husband’s Parkinson’s medications
- Scientists aim for treatment that blocks toxic protein in Parkinson’s
- Cell therapy eases Parkinson’s motor symptoms in early trial